Overview
GTBP market data
Price History
GTBP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$6.94 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.91 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.26 – $2.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $14.5 · P/B 1.44 · P/S 230.17.
Company news
8-K filing — GT Biopharma, Inc. (GTBP)SEC EDGAR · Jun 12, 2026, 8:30 PM
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyBenzinga · Jun 2, 2026, 2:15 PM
EXCLUSIVE: GT Biopharma Implements AI Initiatives To Accelerate Pipeline Discovery, Reduce Costs, Explores Opportunities Beyond OncologyBenzinga · Jun 1, 2026, 11:35 AM
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology RolloutBenzinga · Jun 1, 2026, 11:31 AM
Nasdaq Grants GT Biopharma Additional 180 Days To Regain ComplianceBenzinga · May 22, 2026, 12:15 PM
GT Biopharma Q1 EPS $(0.11) Misses $(0.08) EstimateBenzinga · May 15, 2026, 12:25 PM
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobenewswire Inc · May 14, 2026, 3:15 PM
GT Biopharma shares are trading higher after the company announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550.Benzinga · May 14, 2026, 1:11 PM
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer TypesBenzinga · May 14, 2026, 12:16 PM
EXCLUSIVE: GT Biopharma Announces First Patient Dosed In Phase 1 Trial Of GTB-5550; Company Anticipates Providing Updates In H2 2026 As Enrollment Progresses Through Dose Escalation CohortsBenzinga · May 14, 2026, 12:15 PM